(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”), (“Helix” or the “Company”), a clinical-stage
biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary
technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31,
2021.
- 0 Comments
- FY2021